Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Benlysta 200 mg solution for injection in pre-filled pen {equilateral_black_triangle}

Active Ingredient:
belimumab
Company:  
GlaxoSmithKline UK See contact details
ATC code: 
L04AG04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs Live Chat HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

Dear HCP Letter Belimumab SC_NHSE

{healthcare_pro_orange} For Healthcare Professionals
Short-term availability of belimumab pre-filled pen formulation for subcutaneous (SC) administration for existing patients receiving belimumab solution for injection intravenous (IV) administration during COVID-19 pandemic in the UK.
{pdf_link}

Dear HCP Letter Belimumab SC_Scotland

{healthcare_pro_orange} For Healthcare Professionals
Short-term availability of belimumab pre-filled pen formulation for subcutaneous (SC) administration for existing patients receiving belimumab solution for injection intravenous (IV) administration during COVID-19 pandemic in the UK.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

GlaxoSmithKline UK
Company image
Address
79 New Oxford Street, London, WC1A 1DG, UK
Telephone
0800 221 441
Medical Information e-mail
[email protected]
E-mail
[email protected]
Adverse event reporting email
[email protected]